I agree that this site is using cookies. You can find further informations here.
X
Coggon, Amelia
37  results:
Search for persons X
?
1

In VitroandIn VivoCharacterization of H5N8 High-Pathogenici..:

Foret-Lucas, Charlotte ; Figueroa, Thomas ; Coggon, Amelia...
Microbiology Spectrum.  11 (2023)  1 - p. , 2023
Link: https://doi.org/10.1128/..
 
?
2

Antigenic evolution of contemporary clade 2.3.4.4 HPAI H5 i..:

Lewis, Nicola S ; Banyard, Ashley C ; Essen, Steve...
Vaccine.  39 (2021)  29 - p. 3794-3798 , 2021
Link: https://doi.org/10.1016/..
 
?
3

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
PLOS Pathogens.  17 (2021)  8 - p. e1009427 , 2021
Link: https://doi.org/10.1371/..
 
?
4

In Vitro and In Vivo Characterization of H5N8 High-Pathogen..:

Foret-Lucas, Charlotte ; Figueroa, Thomas ; Coggon, Amelia...
info:eu-repo/semantics/altIdentifier/doi/10.1128/spectrum.04229-22.  , 2023
Link: https://hal.inrae.fr/hal..
 
?
5

In Vitro and In Vivo Characterization of H5N8 High-Pathogen..:

Foret-Lucas, Charlotte ; Figueroa, Thomas ; Coggon, Amelia...
info:eu-repo/semantics/altIdentifier/doi/10.1128/spectrum.04229-22.  , 2023
Link: https://hal.inrae.fr/hal..
 
?
6

In Vitro and In Vivo Characterization of H5N8 High-Pathogen..:

Foret-Lucas, Charlotte ; Figueroa, Thomas ; Coggon, Amelia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927090/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

In Vitro and In Vivo Characterization of H5N8 High-Pathogen..:

Foret-Lucas, Charlotte ; Figueroa, Thomas ; Coggon, Amelia...
info:eu-repo/semantics/altIdentifier/doi/10.1128/spectrum.04229-22.  , 2023
Link: https://hal.inrae.fr/hal..
 
?
8

In Vitro and In Vivo Characterization of H5N8 High-Pathogen..:

Foret-Lucas, Charlotte ; Figueroa, Thomas ; Coggon, Amelia...
info:eu-repo/semantics/altIdentifier/doi/10.1128/spectrum.04229-22.  , 2023
Link: https://hal.inrae.fr/hal..
 
?
9

Opposite Outcomes of the Within-Host Competition between Hi..:

Bessière, Pierre ; Figueroa, Thomas ; Coggon, Amelia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754203/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
info:eu-repo/semantics/altIdentifier/doi/10.1101/2021.02.09.430458.  , 2021
Link: https://anses.hal.scienc..
 
?
11

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.ppat.1009427.  , 2021
Link: https://hal.inrae.fr/hal..
 
?
12

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
info:eu-repo/semantics/altIdentifier/doi/10.1101/2021.02.09.430458.  , 2021
Link: https://anses.hal.scienc..
 
?
13

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
info:eu-repo/semantics/altIdentifier/doi/10.1101/2021.02.09.430458.  , 2021
Link: https://anses.hal.scienc..
 
?
14

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
info:eu-repo/semantics/altIdentifier/doi/10.1101/2021.02.09.430458.  , 2021
Link: https://hal-anses.archiv..
 
?
15

Intranasal type I interferon treatment is beneficial only w..:

Bessière, Pierre ; Wasniewski, Marine ; Picard-Meyer, Evelyne...
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.ppat.1009427.  , 2021
Link: https://hal.inrae.fr/hal..
 
1-15